S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
Log in
NASDAQ:IART

Integra LifeSciences Stock Forecast, Price & News

$68.36
+0.67 (+0.99 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$68.07
Now: $68.36
$69.55
50-Day Range
$54.00
MA: $62.68
$67.78
52-Week Range
$34.21
Now: $68.36
$69.55
Volume513,032 shs
Average Volume398,573 shs
Market Capitalization$5.76 billion
P/E Ratio102.02
Dividend YieldN/A
Beta1.26
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it sells hardware products, such as bone and joint fixation, and joint replacement devices; and implants and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was founded in 1989 and is headquartered in Princeton, New Jersey.
Integra LifeSciences logo

MarketRank

Overall MarketRank

1.38 out of 5 stars

Analyst Opinion: 1.2Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500
Employees4,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 billion
Cash Flow$4.27 per share
Book Value$16.50 per share

Profitability

Net Income$50.20 million

Miscellaneous

Market Cap$5.76 billion
Next Earnings Date2/18/2021 (Confirmed)
OptionableOptionable
$68.36
+0.67 (+0.99 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Integra LifeSciences (NASDAQ:IART) Frequently Asked Questions

How has Integra LifeSciences' stock price been impacted by COVID-19?

Integra LifeSciences' stock was trading at $46.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IART stock has increased by 48.3% and is now trading at $68.3550.
View which stocks have been most impacted by COVID-19
.

Is Integra LifeSciences a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Integra LifeSciences?

Wall Street analysts have given Integra LifeSciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Integra LifeSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Integra LifeSciences
.

How can I listen to Integra LifeSciences' earnings call?

Integra LifeSciences will be holding an earnings conference call on Thursday, February 18th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) announced its earnings results on Wednesday, October, 28th. The life sciences company reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.23. The life sciences company had revenue of $370.23 million for the quarter, compared to analyst estimates of $368.91 million. Integra LifeSciences had a net margin of 4.10% and a return on equity of 14.26%.
View Integra LifeSciences' earnings history
.

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Shares of Integra LifeSciences split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Thursday, January, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $387-389 million, compared to the consensus revenue estimate of $389.05 million.

What price target have analysts set for IART?

11 brokerages have issued 12 month target prices for Integra LifeSciences' stock. Their forecasts range from $46.00 to $73.00. On average, they anticipate Integra LifeSciences' stock price to reach $59.73 in the next twelve months. This suggests that the stock has a possible downside of 12.6%.
View analysts' price targets for Integra LifeSciences
or view Wall Street analyst' top-rated stocks.

Who are some of Integra LifeSciences' key competitors?

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include The Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology Group (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 56, Pay $2.16M)
  • Ms. Carrie L. Anderson, Exec. VP & CFO (Age 52, Pay $705.93k)
  • Mr. Glenn G. Coleman, Exec. VP & COO (Age 53, Pay $1.08M)
  • Mr. Eric Ian Schwartz, Exec. VP, Chief Legal Officer & Sec. (Age 52, Pay $692.5k)
  • Mr. Robert T. Davis Jr., Exec. VP and Pres of Orthopedics & Tissue Technologies (Age 62, Pay $742.41k)
  • Dr. Richard E. Caruso, Founder and Chairman Emeritus (Age 78)
  • Mr. Jeffrey Mosebrook, Sr. VP, Principal Accounting Officer & Corp. Controller (Age 45)
  • Dr. Kenneth E. Burhop Ph.D., Corp. VP & Chief Scientific Officer (Age 67)
  • Mr. William Compton, Chief Information Officer & Sr. VP
  • Mr. Sravan K. Emany, Sr. VP of Strategy, Treasury & Investor Relations

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.64%), Exchange Traded Concepts LLC (0.05%), Diversified Trust Co (0.03%), State of Alaska Department of Revenue (0.01%), Crossmark Global Holdings Inc. (0.01%) and 6 Meridian (0.00%). Company insiders that own Integra LifeSciences stock include Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences
.

Which major investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Crossmark Global Holdings Inc.. Company insiders that have sold Integra LifeSciences company stock in the last year include Glenn Coleman, Lisa Evoli, Peter J Arduini, Richard E Caruso, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences
or view top insider-selling stocks.

Which major investors are buying Integra LifeSciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Exchange Traded Concepts LLC, 6 Meridian, and Diversified Trust Co.
View insider buying and selling activity for Integra LifeSciences
or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $68.36.

How big of a company is Integra LifeSciences?

Integra LifeSciences has a market capitalization of $5.76 billion and generates $1.52 billion in revenue each year. The life sciences company earns $50.20 million in net income (profit) each year or $2.74 on an earnings per share basis. Integra LifeSciences employs 4,000 workers across the globe.

What is Integra LifeSciences' official website?

The official website for Integra LifeSciences is www.integralife.com.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.